Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Pathologists Collaborate to Improve Reporting and Accessibility of Cancer Pathology Findings

By LabMedica International staff writers
Posted on 28 Oct 2013
A new partnership has been formed to provide an electronic application service to enhance cancer pathology reporting and use of datasets.

The College of American Pathologists (CAP; Northfield, IL, USA) and mTuitive, Inc. More...
(Centerville, MA, USA) have forged a collaboration to more effectively capture and report cancer pathology findings by providing a product and service that will facilitate production and use of standardized, encoded, and interoperable data sets for use in patient care, registries, research, and biorepositories.

Together, the CAP and mTuitive have developed “CAP eFRM” – the CAP electronic Forms and Reporting Module, an application incorporating the CAP electronic Cancer Checklists (eCC). Cancer case summaries within 65 cancer protocols are electronically represented within the eCC in addition to two new tumor biomarker reporting templates for colon and lung cancer. eFRM was now presented at the CAP’s annual meeting (CAP 2013, Orlando, FA, USA). “We designed eFRM to help pathologists and laboratories make more effective use of data electronically as they care for patients,” said Charles Roussel, CAP CEO; “This application eases eCC implementation for health care and laboratory system vendors, ultimately benefiting pathologists, laboratory professionals, clinicians, and patients.”

The American College of Surgeons - Commission on Cancer (CoC) has also recognized the value of the CAP cancer protocols and has mandated that pathologists at CoC-approved cancer programs include the required data elements of the cancer protocols in their surgical pathology reports on cancer specimens.

mTuitive's unique method of capturing and reporting structured information provides valuable data for pathology, surgery, oncology, and cancer staging applications. “We believe in and are committed to what the CAP is doing in cancer care and, through our collaboration, eFRM furthers how information technology can improve care for cancer patients,” said John Murphy, CEO, mTuitive.

The CAP and mTuitive will offer two versions of eFRM. The first is a basic, standalone version; the second includes a wider range of functionality and was designed to be integrated within a laboratory information system. Both versions will facilitate broader adoption among pathologists and help simplify the management of content changes to the cancer protocols.

Related Links:

College of American Pathologists (CAP)
mTuitive



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.